Week Ending June 21, 2021

A Social Worker Leads ACCC, and Her Timing Is Perfect
“Improving health equity. Developing practice-based solutions for reducing barriers and improving outcomes. Making the case for supportive care. Building a culture that supports professional well-being. Championing resiliency.”

Targeted Therapy for ‘Undruggable’ Lung Cancer Stems from Decades of UCSF Research
“Over the past two decades, targeted cancer therapies have changed the prognosis for thousands of patients. By targeting the specific genetic mutation behind a patient’s cancer, these therapies have enabled increasing numbers of patients to experience fewer toxic side effects and, often, live free of disease following their treatment.”

PET/CT Effective Measures NSCLC Biomarker, Predicts Therapy Response
“PET/CT images can non-invasively measure levels of a non-small cell lung cancer (NSCLC) biomarker, eliminating the need for biopsy and predicting the patient’s response to therapy.”

AMG 757 Elicits Early Response, Safety in Small Cell Lung Cancer+
“First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021. AMG 757 is a DLL3-targeting bispecific T-cell engager.”

chest radiographyPrognostic Understanding Influences Patients’ Lung Cancer Care Decisions at the End of Life
“A new study of patients with advanced cancer explored relationships between patient perceptions of prognosis and end-of-life care. The study and its findings were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Carlisle Topping of Massachusetts General Hospital in Boston, Massachusetts, and colleagues.”

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
“NEW YORK – Genecast said on Monday that it will launch a clinical trial to assess whether its qPCR-based liquid biopsy test can detect EGFR mutations in early-stage non-small cell lung cancer, or NSCLC, patients.”